2. UroToday Home
  3. Recent Abstracts
  4. Urologic Oncology
  5. Prostate Cancer

GU Cancers Symposium 2013 - Degarelix versus LHRH agonists: Differential skeletal and urinary tract outcomes from an analysis of six comparative randomized clinical trials, by E. David Crawford, MD et al. - Poster

ORLANDO, FL, USA (UroToday.com) - The GnRH antagonist degarelix has a mechanism of action distinct from that of LHRH agonists.

Degarelix directly blocks GnRH receptors producing a rapid and sustained inhibition of testosterone without an initial surge or subsequent microsurges in FSH, LH or testosterone seen with LHRH agonists....Click here to enlarge and view the poster

 

gucancers degarelix versus LHRH agonists thumb

 

Presented by E. David Crawford,1 Neal Shore,2 Kurt Miller,3 Bertrand Tombal,4 Cathrina Karup,5 Anders Malmberg,5 and Bo-Eric Persson6 at the 2013 Genitourinary Cancers Symposium - February 14 - 16, 2013 - Rosen Shingle Creek - Orlando, Florida USA

1University of Colorado Cancer Center, Aurora, CO, USA, 2Atlantic Urology Clinics, Myrtle Beach, SC, USA, 3Charité–Universitätsmedizin Berlin, 10098 Berlin, Germany, 4Université Catholique de Louvain, Brussels, Belgium, 5Ferring Pharmaceuticals A/S, Copenhagen, Denmark, 6Ferring Pharmaceuticals, Saint-Prex, Switzerland

 


gucancerssympalt thumb thumb

View Full 2013 GU Cancers Symposium Coverage